Last reviewed · How we verify
SA001 Mid dose
At a glance
| Generic name | SA001 Mid dose |
|---|---|
| Sponsor | Samjin Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome (PHASE2)
- Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SA001 Mid dose CI brief — competitive landscape report
- SA001 Mid dose updates RSS · CI watch RSS
- Samjin Pharmaceutical Co., Ltd. portfolio CI